RYTM
RHYTHM PHARMACEUTICALS, INC.
$88.38
+0.82%
$6.1B
No data for this timeframe.
Vol
Market Cap$6.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$4.3B
Inst. Activity16 buys / 15 sells
Insider Activity0B / 6S
Insider Net $-$1.4M
SEC Reports4
Press Releases4
Recent Activity
Jun 12, 2026
routine
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
<p align="left">BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RY
May 26, 2026
Press
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthc
Impact 2/10
May 18, 2026
Insider
Smith Hunter C acquired via exercise 3,000 shares
Chief Financial Officer @ $17.87 ($53.6K)
May 15, 2026
Insider
German Christopher Paul acquired via exercise 1,687 shares
Corporate Controller & CAO @ $56.69 ($95.6K)
May 15, 2026
Insider
German Christopher Paul sold 4,643 shares
Corporate Controller & CAO @ $92.21 ($428.1K)
May 12, 2026
Press
Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reducti
Impact 4/10
May 5, 2026
SEC
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -$0.83, beating conse
8-K — Impact 6/10
May 5, 2026
SEC
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beat
PRESS-RELEASE — Impact 7/10
Price Targets
$138.20
+56.4% upside
Strong Buy
Current $88.38
Low $105.00
Median $142.00
High $159.00
15 analysts
$105.00
$159.00
Analyst Ratings
8Strong Buy
12Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 20, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.84 ▼ -3.2% | $-1.03 — $-0.67 | -12% YoY | 11 |
| Next Q | $-0.83 ▼ -4.4% | $-1.10 — $-0.64 | -1% YoY | 11 |
| Current FY | $-3.29 ▼ -3.7% | $-4.02 — $-2.80 | -6% YoY | 11 |
| Next FY | $-0.79 ▼ -23.8% | $-2.58 — $1.18 | 76% YoY | 10 |
Latest Reports
NEUTRAL
Press
2/10
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthc
May 26, 2026
MIXED
8-K
6/10
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -$0.83, beating conse
May 5, 2026
BULLISH
PRESS-RELEASE
7/10
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS loss of -$0.73, beat
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| RA CAPITAL MANAGEMENT, L.P. | $579.8M | — |
| BlackRock, Inc. | $542.4M | — |
| BAKER BROS. ADVISORS LP | $487.4M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $264.5M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Smith Hunter | M | $53.6K |
| May 15, 2026 | German Christopher | M | $95.6K |
| May 15, 2026 | German Christopher | SELL | $428.1K |
| Apr 1, 2026 | Popovits Kimberly | A | $0.00 |
| Apr 1, 2026 | Mazabraud Yann | M | $0.00 |
50 institutional holders with $4.3B total value (48,792,590 shares) as of 2026-Q1. Top holders: NOMURA, RA, BlackRock,. Net buying activity: 16 institutions added/increased vs 15 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 6,666,837 | $579.8M | 13.6% | — |
| 3 | BlackRock, Inc. | 6,237,151 | $542.4M | 12.7% | — |
| 4 | BAKER BROS. ADVISORS LP | 5,604,483 | $487.4M | 11.4% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,040,718 | $264.5M | 6.2% | — |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,967,825 | $258.1M | 6.1% | — |
| 7 | STATE STREET CORP | 2,271,851 | $197.6M | 4.6% | — |
| 8 | GOLDMAN SACHS GROUP INC | 1,965,432 | $170.9M | 4.0% | — |
| 9 | FMR LLC | 1,689,671 | $147.0M | 3.5% | — |
| 10 | Polar Capital Holdings Plc | 1,615,586 | $140.5M | 3.3% | ADD +36.3% |
| 11 | CITADEL ADVISORS LLC | 1,418,619 | $123.4M | 2.9% | — |
| 12 | FEDERATED HERMES, INC. | 1,286,303 | $111.9M | 2.6% | — |
| 13 | ALLIANCEBERNSTEIN L.P. | 910,413 | $97.5M | 2.3% | NEW |
| 14 | Capital Research Global Investors | 1,115,460 | $97.0M | 2.3% | ADD +64.7% |
| 15 | JANUS HENDERSON GROUP PLC | 918,153 | $79.9M | 1.9% | — |
| 16 | Point72 Asset Management, L.P. | 846,801 | $73.6M | 1.7% | ADD +97.2% |
| 17 | Woodline Partners LP | 758,891 | $66.0M | 1.5% | — |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 725,744 | $63.1M | 1.5% | — |
| 19 | MORGAN STANLEY | 703,978 | $61.2M | 1.4% | ADD +40.0% |
| 20 | Pictet Asset Management Holding SA | 667,046 | $57.3M | 1.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | ADD | 1,185,392 | 1,615,586 | +36.3% | $140.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 429,420 | 846,801 | +97.2% | $73.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 224,484 | 628,667 | +180.0% | $54.7M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | 1,285,222 | 436,546 | -66.0% | $38.0M | 2026-Q1 |
| Artisan Partners Limited Partnership | ADD | 263,591 | 390,669 | +48.2% | $34.0M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 261,160 | 383,957 | +47.0% | $33.4M | 2026-Q1 |
| Invesco Ltd. | ADD | 291,150 | 364,306 | +25.1% | $31.7M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | NEW | — | 131,674 | — | $10.2M | 2026-Q1 |
| WCM INVESTMENT MANAGEMENT, LLC | ADD | 44,805 | 80,620 | +79.9% | $6.2M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 123,537 | 62,936 | -49.1% | $5.5M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 72,282 | 52,967 | -26.7% | $4.6M | 2026-Q1 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | ADD | 34,127 | 46,887 | +37.4% | $4.1M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | 2,415 | 43,872 | +1716.6% | $3.8M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 55,050 | 38,778 | -29.6% | $3.4M | 2026-Q1 |
| LAZARD ASSET MANAGEMENT LLC | ADD | 25,571 | 32,888 | +28.6% | $2.9M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | TRIM | 53,145 | 30,190 | -43.2% | $2.6M | 2026-Q1 |
| STRS OHIO | DOUBLED | 12,000 | 28,914 | +141.0% | $2.5M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 45,381 | 20,504 | -54.8% | $1.8M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 32,018 | 19,151 | -40.2% | $1.7M | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 75,141 | 17,775 | -76.3% | $1.5M | 2026-Q1 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | 24,334 | 9,219 | -62.1% | $801.8K | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | ADD | 6,080 | 8,463 | +39.2% | $736.0K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | ADD | 4,659 | 6,938 | +48.9% | $603.4K | 2026-Q1 |
| Rockefeller Capital Management L.P. | NEAR_EXIT | 452,897 | 4,844 | -98.9% | $421.3K | 2026-Q1 |
| Swiss Life Asset Management Ltd | ADD | 2,653 | 3,341 | +25.9% | $290.6K | 2026-Q1 |
10 unique insiders with 50 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Smith Hunter C | Chief Financial Officer | EXERCISE | 3,000 | $17.87 | $53.6K |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | EXERCISE | 1,687 | $56.69 | $95.6K |
| May 15, 2026 | German Christopher Paul | Corporate Controller & CAO | SELL | 4,643 | $92.21 | $428.1K |
| Apr 1, 2026 | Popovits Kimberly J | Director | AWARD | 6,808 | — | — |
| Apr 1, 2026 | Mazabraud Yann | EVP, Head of International | EXERCISE | 12,875 | — | — |
| Apr 1, 2026 | Popovits Kimberly J | Director | AWARD | 10,257 | — | — |
| Apr 1, 2026 | Mazabraud Yann | EVP, Head of International | EXERCISE | 10,375 | — | — |
| Mar 12, 2026 | Mathers Edward T | Director | J | 4,199 | — | — |
| Mar 4, 2026 | German Christopher Paul | Corporate Controller & CAO | EXERCISE | 1,500 | $17.97 | $27.0K |
| Mar 2, 2026 | Smith Hunter C | Chief Financial Officer | EXERCISE | 6,099 | $6.80 | $41.5K |
| Mar 2, 2026 | Mathers Edward T | Director | J | 4,198 | — | — |
| Mar 2, 2026 | Mazabraud Yann | EVP, Head of International | AWARD | 35,000 | — | — |
| Mar 1, 2026 | German Christopher Paul | Corporate Controller & CAO | EXERCISE | 1,162 | — | — |
| Feb 12, 2026 | Smith Hunter C | Chief Financial Officer | SELL | 292 | $96.26 | $28.1K |
| Feb 11, 2026 | Smith Hunter C | Chief Financial Officer | AWARD | 37,500 | — | — |
| Feb 11, 2026 | Smith Hunter C | Chief Financial Officer | AWARD | 25,000 | — | — |
| Feb 11, 2026 | Smith Hunter C | Chief Financial Officer | SELL | 2,266 | $98.37 | $222.9K |
| Feb 11, 2026 | Garfield Alastair | Chief Scientific Officer | AWARD | 25,000 | — | — |
| Feb 11, 2026 | Garfield Alastair | Chief Scientific Officer | AWARD | 16,650 | — | — |
| Feb 11, 2026 | German Christopher Paul | Corporate Controller & CAO | AWARD | 5,215 | — | — |
| Feb 11, 2026 | Lee Jennifer Kayden | EVP, Head of North America | AWARD | 32,500 | — | — |
| Feb 11, 2026 | Lee Jennifer Kayden | EVP, Head of North America | AWARD | 21,650 | — | — |
| Feb 11, 2026 | Mazabraud Yann | EVP, Head of International | AWARD | 23,350 | — | — |
| Feb 11, 2026 | Shulman Joseph | Chief Technical Officer | AWARD | 22,500 | — | — |
| Feb 11, 2026 | Shulman Joseph | Chief Technical Officer | AWARD | 15,000 | — | — |
| Feb 11, 2026 | Meeker David P | President and CEO | AWARD | 107,850 | — | — |
| Feb 11, 2026 | Meeker David P | President and CEO | AWARD | 71,900 | — | — |
| Feb 11, 2026 | Cramer Pamela J. | Chief Human Resources Officer | AWARD | 17,500 | — | — |
| Feb 11, 2026 | Cramer Pamela J. | Chief Human Resources Officer | AWARD | 11,650 | — | — |
| Feb 10, 2026 | Smith Hunter C | Chief Financial Officer | SELL | 1,913 | $102.66 | $196.4K |
| Feb 5, 2026 | Smith Hunter C | Chief Financial Officer | SELL | 3,381 | $106.06 | $358.6K |
| Feb 4, 2026 | Smith Hunter C | Chief Financial Officer | SELL | 1,500 | $104.74 | $157.1K |
| Feb 1, 2026 | Meeker David P | President and CEO | EXERCISE | 68,713 | — | — |
| Feb 1, 2026 | Meeker David P | President and CEO | TAX W/H | 31,522 | $108.99 | $3.4M |
| Feb 1, 2026 | Meeker David P | President and CEO | EXERCISE | 14,125 | — | — |
| Feb 1, 2026 | Smith Hunter C | Chief Financial Officer | EXERCISE | 4,062 | — | — |
| Feb 1, 2026 | Smith Hunter C | Chief Financial Officer | EXERCISE | 26,000 | — | — |
| Feb 1, 2026 | Smith Hunter C | Chief Financial Officer | TAX W/H | 10,750 | $108.99 | $1.2M |
| Feb 1, 2026 | Cramer Pamela J. | Chief Human Resources Officer | EXERCISE | 13,293 | — | — |
| Feb 1, 2026 | Cramer Pamela J. | Chief Human Resources Officer | TAX W/H | 4,731 | $108.99 | $515.6K |
| Feb 1, 2026 | Cramer Pamela J. | Chief Human Resources Officer | EXERCISE | 2,343 | — | — |
| Feb 1, 2026 | Mazabraud Yann | EVP, Head of International | EXERCISE | 5,500 | — | — |
| Feb 1, 2026 | Shulman Joseph | Chief Technical Officer | EXERCISE | 16,968 | — | — |
| Feb 1, 2026 | Shulman Joseph | Chief Technical Officer | TAX W/H | 6,507 | $108.99 | $709.2K |
| Feb 1, 2026 | Shulman Joseph | Chief Technical Officer | EXERCISE | 2,656 | — | — |
| Feb 1, 2026 | Lee Jennifer Kayden | EVP, Head of North America | EXERCISE | 22,612 | — | — |
| Feb 1, 2026 | Lee Jennifer Kayden | EVP, Head of North America | TAX W/H | 9,237 | $108.99 | $1.0M |
| Feb 1, 2026 | Lee Jennifer Kayden | EVP, Head of North America | EXERCISE | 3,437 | — | — |
| Feb 1, 2026 | German Christopher Paul | Corporate Controller & CAO | EXERCISE | 3,613 | — | — |
| Feb 1, 2026 | German Christopher Paul | Corporate Controller & CAO | TAX W/H | 1,138 | $108.99 | $124.0K |
4 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 6.0/10.
MIXED
8-K
6/10
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M (up 59% YoY from $37.7M) and GAAP EPS of -
May 5, 2026
BULLISH
PRESS-RELEASE
7/10
Rhythm Pharmaceuticals reported Q1 2026 revenue of $60.1M, beating the $56.1M consensus, and an EPS
May 5, 2026
NEUTRAL
8-K
3/10
Rhythm Pharmaceuticals announced the appointment of Kimberly Popovits to its Board of Directors and
Apr 3, 2026
BULLISH
8-K
8/10
Rhythm Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, with Q4
Feb 26, 2026
NEUTRAL
2/10
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jeff
May 26, 2026
NEUTRAL
4/10
Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including sig
May 12, 2026
BULLISH
7/10
Rhythm Pharmaceuticals received European Commission approval for IMCIVREE (setmelanotide) to treat a
May 1, 2026
BULLISH
8/10
Rhythm Pharmaceuticals announced additional positive 52-week data from its Phase 3 TRANSCEND trial s
Mar 1, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 8 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$138.20 mean target
+56.4% upside
Strong Buy (1.38)
$105.00 Low
$159.00 High
| Metric | Value |
|---|---|
| Current Price | $88.38 |
| Target Low | $105.00 |
| Target Mean | $138.20 |
| Target Median | $142.00 |
| Target High | $159.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.84 | $-1.03 | $-0.67 | -12.3% | -3.2% | 4↑ 6↓ | $0.1B | 39.2% | 11 |
| Next Q 2026-09-30 |
$-0.83 | $-1.10 | $-0.64 | -0.9% | -4.4% | 4↑ 6↓ | $0.1B | 54.0% | 11 |
| Current FY 2026-12-31 |
$-3.29 | $-4.02 | $-2.80 | -5.8% | -3.7% | 4↑ 7↓ | $0.3B | 57.1% | 11 |
| Next FY 2027-12-31 |
$-0.79 | $-2.58 | $1.18 | 75.8% | -23.8% | 3↑ 5↓ | $0.5B | 81.5% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.842 | |
| 7d ago | $-0.842 | |
| 30d ago | $-0.816 | -0.026 |
| 60d ago | $-0.807 | -0.035 |
| 90d ago | $-0.768 | -0.075 |
10 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 23, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Mar 17, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 17, 2026 | Needham | MAINTAIN | Buy | Buy |
| Mar 12, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Mar 2, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 27, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 26, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 19, 2026 | RBC Capital | INITIATE | — | Outperform |
| Jan 20, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 17, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 12 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 8 | 12 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 8 | 12 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 8 | 12 | 2 | 0 | 0 | 91% | |
| Feb 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% | |
| Jan 1, 2026 | 8 | 11 | 2 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
routine
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
<p align="left">BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c
May 29, 2026
routine
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
<p align="left">BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical c
May 26, 2026
fda
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
<p align="left">BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical co
May 12, 2026
m_and_a
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
<p align="center"><em>– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acq
May 12, 2026
short_interest
FTD: RYTM — 9,222 shares ($0.8M) failed to deliver
Settlement: 20260512, Price: $87.39, FTD Value: $805,910.58, RHYTHM PHARMACEUTICALS INC COM
May 5, 2026
earnings
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
<p align="center"><em>-- IMCIVREE</em><sup><em>®</em></sup><em> (setmelanotide)</em><em> launched in the U.S. for acquired hypothalamic obesity; more
May 5, 2026
earnings_calendar
RYTM Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
short_volume
Short Volume: RYTM — 65.2% short (0.4M / 0.7M)
Short: 437,297 | Exempt: 48 | TRF Vol: 670,228 | Short Ratio: 65.2% | Off-exchange volume (dark pool + OTC)
May 1, 2026
Clinical Trial
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Phase Phase 2 — COMPLETED
May 1, 2026
clinical_trial_readout
Results Pending: LB54640 (Phase 2) — Completed 81d ago
Trial: A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Sponsor: Rhythm Pharmaceuticals, Inc.
Phase: Phase 2 | C
May 1, 2026
m_and_a
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
<p align="center"><em>-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity --</em></p> <p align="center"><em>-- Eur
Apr 28, 2026
short_interest
FTD: RYTM — 9,990 shares ($0.9M) failed to deliver
Settlement: 20260428, Price: $85.20, FTD Value: $851,148, RHYTHM PHARMACEUTICALS INC COM
Apr 3, 2026
other
Rhythm Pharmaceuticals Announces Changes to Board of Directors
<p align="center"><em>-- Kim Popovits appointed as new Director; Ed Mathers to depart --</em></p> <p align="left">BOSTON, April 03, 2026 (GLOBE NEWS
Apr 1, 2026
clinical_trial_readout
Results Pending: LB54640 (Phase 2) — Completed 51d ago
Trial: A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Sponsor: Rhythm Pharmaceuticals, Inc.
Phase: Phase 2 | C
Mar 31, 2026
short_volume
Short Volume: RYTM — 57.7% short (0.5M / 0.9M)
Short: 543,535 | Exempt: 128 | TRF Vol: 941,445 | Short Ratio: 57.7% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
clinical_trial_readout
Results Pending: LB54640 (Phase 2) — Completed 49d ago
Trial: A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
Sponsor: Rhythm Pharmaceuticals, Inc.
Phase: Phase 2 | C
Mar 19, 2026
FDA
IMCIVREE
Supplemental Approval — Efficacy — SETMELANOTIDE — SOLUTION — SUBCUTANEOUS
Mar 19, 2026
FDA
IMCIVREE
Supplemental Approval — Efficacy — SETMELANOTIDE — SOLUTION — SUBCUTANEOUS